Grzeszczak W, Zukowska-Szczechowska E, Galwas B, Gumprecht J, Jendryczko A, Małecka J
Katedra i Klinika Chorób Wewnetrznych i Zawodowych Sl. AM w Zabrzu.
Pol Arch Med Wewn. 1994 Apr;91(4):247-56.
Several groups have reported increased blood lead (Pb) concentrations in patients with chronic renal failure (CRF) and haemodialysed but normal concentrations were observed by the others. The present study aimed to assess: 1. Pb concentrations in patients with CRF and influence of the haemodialysis on these concentrations. 2. The influence of the erythropoietin (EPO) therapy on the Pb concentrations. 3. The influence of long-term haemodialysis therapy on the Pb concentrations. 101 patients with CRF and 23 healthy subjects were examined. Patients with CRF were divided into two groups: nonhaemodialysed (group I) and haemodialysed (group II). Group two consisted of some subgroups: treated with EPO;--without EPO therapy;--haemodialysed 1-50 months;--51-100 months and > 100 months. Creatinine, Pb, haemoglobin and haematocrit concentrations were measured in all examined patients. Significantly higher Pb concentrations in CRF patients comparing to healthy subjects were found. Among CRF patients significantly lower Pb concentrations were observed in group I and did not differ from those in the control group. After haemodialysis Pb blood concentrations significantly decreased in all examined subgroups. In EPO subgroup in comparison with CRF patients without EPO therapy lower but not significantly Pb concentrations were observed. No significant changes between short and long-term haemodialysed patients were found.
多个研究小组报告称,慢性肾衰竭(CRF)患者和接受血液透析患者的血铅(Pb)浓度升高,但其他研究小组观察到的浓度正常。本研究旨在评估:1. CRF患者的铅浓度以及血液透析对这些浓度的影响。2. 促红细胞生成素(EPO)治疗对铅浓度的影响。3. 长期血液透析治疗对铅浓度的影响。对101例CRF患者和23名健康受试者进行了检查。CRF患者分为两组:未进行血液透析组(第一组)和进行血液透析组(第二组)。第二组又分为一些亚组:接受EPO治疗;未接受EPO治疗;血液透析1 - 50个月;51 - 100个月以及超过100个月。测量了所有受检患者的肌酐、铅、血红蛋白和血细胞比容浓度。发现CRF患者的铅浓度显著高于健康受试者。在CRF患者中,第一组的铅浓度显著较低,且与对照组无差异。血液透析后,所有受检亚组的血铅浓度均显著下降。在EPO亚组中,与未接受EPO治疗的CRF患者相比,观察到铅浓度较低但无显著差异。短期和长期血液透析患者之间未发现显著变化。